Drug Patch Gets OK for Severe Alzheimer’s
The FDA has expanded the indication for transdermal rivastigmine to include patients with severe Alzheimer’s disease. The approval means that the transdermal agent is indicated for use in any Alzheimer’s patient, irrespective of disease stage or severity. The expanded indication
2 min read